NFE2L2 and lung cancer: Approximately 30% of human lung cancers gain mutations affecting Keap1 or NFE2L2 (encoding Nrf2), which lead to the stabilization of Nrf2, influence the nuclear transport of BACH1/Nrf2, and upregulate the expression of HO-1, thereby combating oxidative stress [22].